MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions (T2*MRI)

Weill Cornell Medicine (WCM)

Status: Completed

Conditions: Myelodysplastic Syndrome (MDS)

Treatments: Other: T2* Cardiac and Liver MRI

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00749372

CICL670A US23T

0803009687

Details and patient eligibility

About

A known risk of red blood cell transfusions is that it puts excess iron into the patient's body. Researchers are continually seeking the most effective method of measuring iron concentration. The purpose of this study is to determine how much iron has been deposited in a patient's heart and liver as a result of having received red blood cell transfusions using magnetic resonance imaging (MRI).

Enrollment: 15 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or Female patients will need documentation of diagnosis of Myelodysplastic Syndrome by previous bone marrow exam
• Male or female patients with MDS who have received at least 50 units of Red Blood Cell Transfusions.
• Serum ferritin > 1,000
• Written informed consent by the patient.

Exclusion criteria

• Contraindication to MRI, including cardiac pacemaker, brain aneurysm clip, implanted neurostimulator, insulin pump, cochlear implant, metal slivers in the eyes, intrauterine device or any other MRI incompatible metal implants or intractable claustrophobia.

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

1

Other group

Description:

Patients who meet eligibility will be sent for radiographic imaging to include T2\* cardiac and liver MRI to ascertain quantification of organ-specific iron concentrations as well as cardiac left ventricular ejection fraction.

Treatment:

Other: T2* Cardiac and Liver MRI